2021-2030 Analysis and Review Voglibose Market
Voglibose Market By Clinical Application (Postprandial Hyperglycemia and Type 1b Glycogen Storage Disease), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027
The voglibose market was valued at USD3,549.3Mn by 2019. As per the research citings provided by the World Health Organization (WHO), it is estimated that more than 422 million people throughout the globe are suffering from type 2 diabetes mellitus. Increasing public health awareness pertaining to diabetes has resulted in the early detection of postprandial hyperglycemia which further propels the voglibose market.
Voglibose is categorized as an α glucosidase inhibitors, it was discovered in Japan in 1981 when it was isolated from the culture media producing Streptomyces hygroscopicity var. limonons and was commercially available since 1995 for the treatment of postprandial hyperglycemia. It exerts an anti-hypoglycemic action from a reversible inhibition of the membrane-bound intestinal enzyme α glycosidase hydrolyze and prevents the increase in blood glucose level post-meal.
The major segments related to the voglibose market are:
By Clinical Application (2017–2027; US$ Mn)
Postprandial Hyperglycemia
Type 1b Glycogen Storage Disease
By Distribution Channel (2017–2027; US$ Mn)
Hospital Pharmacy
Retail Pharmacy
Others
Geography Segment(2017–2027; US$ Mn)
North America
United States
Canada
Europe
United Kingdom
Germany
Rest of Europe
Asia Pacific
China
Japan
Rest of Asia Pacific
Latin America (LATAM)
Brazil
Mexico
Rest of Latin America
Middle East and Africa (MEA)
GCC
Rest of MEA
Justification for study?
Report gist?
Significant customers?
Segment Analysis
Postprandial hyperglycemia is defined by the plasma glucose level exceeding 140mg/dl, it usually occurs when there is some kind of impairment of the first phase of insulin response which causes a reduced insulin sensitivity in the peripheral tissues with lower suppression of hepatic glucose post meals. A significant rise in physical inactivity and an unhealthy lifestyle together drive the demand for voglibose in the treatment of postprandial hyperglycemia. Type 1b glycogen storage disease is a rare disease that usually occurs in 1 per 100,000 births throughout the globe. Voglibose has been extensively studied in the clinical trials for its therapeutic efficacy and safety for the treatment of type 1b glycogen storage disease.
Hospital pharmacy is presently dominating the distribution channel segment for the voglibose market. The chief contributing factor responsible for its impressive market growth is the rising public health awareness resulting in a large number of patients visiting hospital pharmacy with prescription of voglibose for the treatment of type 2 diabetes mellitus. Retail pharmacy is expected to register magnificent market growth during the forecast period owing to the exponential growth in the generic drug market worldwide and the capability to serve pre-diabetic patients in remote locations.
North America is holding the largest market share in the voglibose market. The rising prevalence of type 2 diabetes primarily determines the overwhelming market performance for voglibose in the regional segment. As per the latest statistics brought forward by the Center for Disease Control and Prevention, (CDC), approximately 34 million Americans are suffering from type 2 diabetes. Affordable reimbursement scenario provided for the use of voglibose in the treatment of postprandial hyperglycemia further consolidates the voglibose market growth in the region. Europe is in the 2nd position in the regional segment for the voglibose market. As per the latest report presented by the European Commission, the type 1b glycogen storage disease occurs in 1 in 20,000 Ashkenazi Jews population inhabiting the Eastern European region. The supportive regulatory environment provided by the European Medical Agency (EMA) for the sale and distribution of voglibose further propels the market growth in the region. Asia Pacific is keen to showcase rampant market growth in the near future on account of a significant rise in obesity, sedentary lifestyle, consumption of junk food causing the early occurrence of type 2 diabetes in the young population in the region.
$4,600 | |
$6,600 | |
$9,500 |
Request customization |
Get market alerts |
Ask for regional data |
Ask for country-specific data |